|
|
||||||||
CUTTING EDGE |
Division of Developmental Immunology, La Jolla Institute for Allergy and Immunology, San Diego, CA 92121
| Abstract |
|---|
|
|
|---|
7 integrin-dependant intestinal localization, but the importance of
7 integrins for Treg function is unknown. In this study, we show that
7/ Treg were effective in preventing colitis. Treg expanded in vivo to the same extent as CD4+CD45RBhigh T cells after transfer and they did not inhibit CD4+CD45RBhigh T cell expansion in lymphoid tissues, although they prevented the accumulation of Th1 effector cells in the intestine.
7/ Treg were significantly reduced in the large intestine, however, compared with wild-type Treg, and regulatory activity could not be recovered from the intestine of recipients of
7/ Treg. These data demonstrate that Treg can prevent colitis by inhibiting the accumulation of tissue-seeking effector cells and that Treg accumulation in the intestine is dispensable for colitis suppression. | Introduction |
|---|
|
|
|---|
secretion (4, 5, 6, 7, 8).
Efficient localization and retention of lymphocytes in the intestine are dependent on
7-containing integrins (9).
4
7 integrin binds to the mucosal addressin cell adhesion molecule 1, which facilitates extravasation of lymphocytes through high endothelial venules in the mucosa (10, 11). The
E
7 integrin may facilitate entry and/or retention of lymphocytes into the epithelial layer via interactions with E-cadherin-expressing epithelial cells (12, 13, 14). The importance of
7 integrins is evidenced by the paucity of intestinal lymphocytes in mice lacking
7 integrins (
7/ mice) (15). There also is evidence from experimental models that interaction of
4
7 integrin with mucosal addressin cell adhesion molecule 1 is important for colitis pathogenesis (16, 17, 18). It is not known, however, whether CD4+CD25+ Treg likewise require
7 integrin expression and intestinal homing to prevent disease. In this study, we have analyzed these issues by comparing transferred
7+/+ and
7/ Treg for their ability to accumulate in different sites and their effects on cotransferred CD4+CD45RBhigh T cells and colitis induction.
| Materials and Methods |
|---|
|
|
|---|
C57BL/6J, C57BL/6 CD45.1 congenic, and C57BL/6
7/ mice (15) were obtained from The Jackson Laboratory. C57BL/6 CD45.1 congenic RAG2/ mice were obtained from the Taconic Laboratory. Studies were approved by the Institutional Animal Care and Use Committee.
Adoptive transfer of T cells
Splenocytes were enriched for CD4+ cells by positive selection on MACS columns using anti-CD4 microbeads (Miltenyi Biotec). Cells then were stained with FITC anti-CD45RB (16A), PE anti-CD25 (PC61), and PE-Cy5 anti-CD4 (GK1.5) (BD Pharmingen) and sorted into CD4+CD25CD45RBhigh (CD45.1+ donors) or CD4+CD25+CD45RBlow (
7+/+ or
7/ CD45.2+ donors) populations. CD45.1 RAG2/ recipients were injected i.v. with 5 x 105 CD4+CD25CD45RBhigh lymphocytes in the presence or absence of 0.5 or 1 x 105 sorted CD4+CD25+CD45RBlow lymphocytes from either
7+/+ or
7/ mice.
Assessment of disease
Recipient mice were weighed weekly and observed for signs of illness. Intestinal tissue samples were fixed, embedded, stained, and scored as described previously (19). All samples were coded and scored blinded to the experimental conditions.
Flow cytometric analysis of lymphocytes
Mucosal lymphocytes were isolated according to a previously published method (20). Isolated splenocytes, peripheral lymph node cells, mesenteric lymph node (MLN) cells, intraepithelial lymphocyte, and lamina propria lymphocyte (LPL) were stained with PE-Cy5 or allophycocyanin anti-TCR
(H57-597), FITC anti-CD45.1 (A20), PE anti-CD25 (PC61), and PE-Cy5 or allophycocyanin anti-CD4 (GK1.5) (BD Pharmingen).
In vitro stimulation of lymphocytes
Large intestine IEL (LIEL) or large intestine LPL (LLPL) at 106/ml were stimulated with 10 µg/ml anti-CD3
clone 2C11 (BD Pharmingen). In cocultures, 1 x 105 CFSE-labeled CD4+CD45RBhigh T cells were cultured at a 1:1 ratio with total CD4+ LIEL/LLPL isolated from RAG/ transfer recipients. LIEL and LLPL were combined and further purified by positive selection with anti-CD4 microbeads, and the cells were stimulated with 5 x 104 T cell-depleted spleen cells as APC and 1 µg/ml anti-CD3
for 48 h.
For ELISA or coculture experiments, supernatants or cells were harvested after 48 h. IFN-
was detected by ELISA following the manufacturers instructions (BD Pharmingen). For intracellular cytokine analysis, cells were stimulated for 2 h before the addition of GolgiStop (BD Pharmingen) and cultured for an additional 6 h. Cells were permeabilized and stained with allophycocyanin-labeled anti-IL-4 clone BVD4-1D11 and PE-labeled anti-IFN clone XMG1.2 (BD Pharmingen).
| Results |
|---|
|
|
|---|
7/ Treg prevent colitis
Transfer of splenic CD4+CD45RBhigh T cells into RAG/ mice led to a severe wasting syndrome by 612 wk (Fig. 1a), but at 12 wk after reconstitution with CD4+CD45RBhigh T cells and
7+/+ Treg, all recipients appeared healthy and continued to gain weight (Fig. 1a). To assess the role of intestinal localization in Treg function, we used
7/ CD4+CD25+ Treg. Because it has been reported that
E
7-expressing CD4+CD25+ Treg are more potent than their
E
7-negative counterparts from wild-type mice (21), we assessed the potency of CD4+CD25+ Treg from
7/ mice to ascertain they are not impaired. CD4+CD25+ Treg from
7/ mice were as capable as wild-type cells in inhibiting the proliferation of CD4+CD45RBhigh T cells in vitro (data not shown). We reasoned that
7/CD4+CD25+ Treg might not efficiently repopulate the intestine of recipients. Interestingly, however,
7/ Treg were also capable of inhibiting all clinical signs of colitis, including weight loss (Fig. 1a).
|
7+/+ or
7/ Treg displayed no histological evidence of intestinal inflammation (Fig. 1b). Tissue sections from CD4+CD45RBhigh T cell recipients had an average histological score of 6.1 ± 0.3 (Fig. 1a) and were characterized by inflammatory infiltrate, epithelial hyperplasia, crypt cell damage, and goblet cell depletion. By contrast, when 1 x 105 Treg from either
7+/+ or
7/ mice were cotransferred, the average histological scores were zero (Fig. 1a). Transfer of only 5 x 104
7/ Treg also completely prevented colitis pathogenesis by 10 times as many CD4+CD45RBhigh T cells (data not shown). This is a higher ratio of pathogenic cells to Treg than has been used in most other experiments, suggesting that the
7/ Treg are highly effective at preventing disease. It remains possible, however, that wild-type Treg are effective at even lower ratios and that
7/ Treg are slightly impaired compared to wild-type cells.
7/ Treg are underrepresented in the intestine
To compare the in vivo expansion of CD4+CD45RBhigh T cells and Treg, tissues were analyzed 1012 wk after transfer for the ratio of CD4+CD45RBhigh (CD45.1+) T cells:CD4+CD25+ (CD45.2+) Treg. When the input ratio of CD4+CD45RBhigh:
7+/+CD4+CD25+ Treg was 5:1, recipients approximately maintained this 5:1 ratio in almost all organs analyzed, including LPL from the large intestine (Fig. 2). This demonstrates that Treg expanded in vivo in immune-deficient mice to a similar extent as CD4+CD45RBhigh T cells. RAG/ mice cotransferred with CD4+CD45RBhigh T cells and
7/CD4+CD25+ Treg also maintained ratios of CD4+CD45RBhigh T cells:Treg similar to the input 5:1 ratio in the spleen and lymph nodes, but not in the intestine (Fig. 2). In LLPL of recipients of
7/CD4+CD25+ Treg, the ratio of CD4+CD45RBhigh T cells:Treg was >20:1. This difference compared with cotransfer of
7+/+CD4+CD25+ Treg was statistically significant (p < 0.05). The ratios of CD4+CD45RBhigh T cells:
7/ Treg were even higher in LIEL.
|
In addition to the ratios, the absolute numbers of donor CD4+CD45RBhigh lymphocytes and Treg in RAG/ recipients were analyzed. In the absence of Treg, CD4+CD45RBhigh T cells accumulated in all recipient sites analyzed (Table I). As might be expected, this accumulation was especially evident in the large intestinal lamina propria, where the bacterial antigenic load is greatest and inflammation was pronounced. When either
7+/+ or
7/CD4+CD25+ Treg were cotransferred, there was no difference in the accumulation of CD4+CD45RBhigh T cells in lymph nodes and an
2-fold decrease in the spleen. The presence of Treg had the greatest impact, however, on CD4+CD45RBhigh T cell accumulation in the large intestine. In the lamina propria, CD4+CD45RBhigh T cell numbers were 7.9- to 4.3-fold reduced in recipients of
7+/+ and
7/ CD4+CD25+ Treg, respectively, compared with recipients without Treg (Table I). A similar reduction in donor-derived CD4+CD45RBhigh T cells was observed in the epithelium.
|
production is suppressed by Treg
A hallmark of the transfer model of colitis is secretion of IFN-
and TNF-
by donor lymphocytes in the lamina propria (22). Consistent with this, LLPL derived from recipient mice injected with CD4+CD45RBhigh T cells secreted 36.4 ± 8.5 (SEM) ng/ml IFN-
upon in vitro restimulation with anti-CD3
mAb. LLPL cytokine production was decreased to 1.7 ± 0.3 ng/ml when the recipients had received a 5:1 ratio of CD4+CD45RBhigh T cells:
7+/+ Treg.
7/ Treg had a similar effect, with 1.4 ± 0.3 ng/ml IFN-
released. This was confirmed by intracellular cytokine staining of anti-CD3-stimulated LIEL or LLPL from the recipients. Cotransfer of either
7+/+ or
7/CD4+CD25+ Treg greatly reduced the percentage of progeny of the donor CD4+CD45RBhigh T cells that produced IFN-
(Fig. 3), while no intracellular IL-4 was detected. Cotransfer of
7+/+ or
7/CD4+CD25+ Treg also led to a decreased percentage of LIEL that could be stimulated to produce TNF, but there was no decrease in the percentage of TNF producing LLPL or cells from MLN (data not shown). Since the absolute number of donor T cells in the large intestine was markedly decreased (Table I), however, the absolute number of TNF-producing cells in the intestine was correspondingly decreased.
|
7 integrins are required for Treg activity in the intestine
The very low numbers of Treg in the intestine of protected RAG/ recipient mice were not sufficient for purification and in vitro assay, although it remained possible that the few cells in the intestine were extremely potent. To address this issue,
7+/+ or
7/ Treg were cotransferred with CD4+CD45RBhigh T cells into RAG/ mice, and the combined total CD4+ LIEL and LLPL from the recipients were assessed for their ability to inhibit the proliferation of naïve CD4+CD45RBhigh cells from the spleen of wild-type mice (Fig. 4a). As total CD4+ cells from the intestine of recipient mice were added to the naive spleen cells, the majority could not have been Treg. We reasoned, however, that if Treg acted locally to prevent inflammation, then in a 1/1 dilution in culture they still might be able to prevent proliferation in vitro. Intestinal T cells from mice cotransferred with
7+/+ Treg and CD4+CD45RBhigh T cells prevented the in vitro proliferation by CFSE-labeled, naive spleen cells (Fig. 4b). In dramatic contrast, intestinal T cells obtained from mice that had been cotransferred with
7/ Treg could not inhibit naive T cell proliferation in vitro. These data indicate that although
7+/+ Treg in the intestine contributed to ex vivo regulatory function, this activity was not a prerequisite for protection from colitis in vivo.
|
| Discussion |
|---|
|
|
|---|
7/CD4+CD25+ Treg are impaired in their ability to populate the intestine during cotransfer with CD4+CD45RBhigh T cells into RAG/ mice and therefore are greatly out numbered in the large intestine by progeny of the CD4+CD45RBhigh donor T cells. Despite this, they are capable of preventing intestinal inflammation and the associated Th1 polarization of pathogenic T cells in the intestine as Treg from wild-type mice. Therefore, while T cell pathogenesis in this colitis model is dependent on
7 integrin expression (16), T cell-mediated regulation is not.
Alteration of the initial differentiation of naive T cells in the periphery may be a fundamental mechanism as to how Treg prevent inflammation in the transfer model of colitis (23). Consistent with this possibility, we showed that both
7/ and
7+/+CD4+CD25+ Treg migrated to the spleen and lymph nodes and expanded as efficiently there as CD4+CD45RBhigh T cells. In experimental autoimmune encephalomyelitis (24) and diabetes in mice (25), it also was shown that transferred, protective Treg accumulated primarily in the peripheral lymph nodes and failed to infiltrate the target organ.
Although the
7 independence of Treg action is proven, we cannot formally exclude the possibility that the very few
7/ Treg in the intestine contributed to the prevention of colitis. It is evident, however, that even with a 10-fold excess of CD4+CD45RBhigh T cells transferred, and impaired mucosal localization of Treg due to
7 deficiency, that Treg function was not markedly diminished. Furthermore, because no regulatory activity could be detected in the intestine of recipients that received
7/ Treg, it is highly unlikely that the very few
7/ Treg in the intestine were exceptionally potent suppressors.
The mixture of CD4+ T cells in the large intestine after cotransfer of wild-type Treg and CD4+CD45RBhigh T cells could prevent the proliferation of naive T cells in vitro. Our data therefore are consistent with the hypothesis that wild-type Treg can act in the intestine as well as in lymph nodes. It remains to be determined whether the local Treg stimulated some of the progeny of the CD4+CD45RBhigh T cells in the intestine to convert to Treg (26), although this did not happen when
7/ Treg were transferred. It was reported recently that CD4+CD25+ Treg can treat established colitis, and it was suggested that in this case the Treg were regulating pathogenesis in the intestine (27). It is conceivable that the major site of action of Treg will depend on the experimental model, with the extent of preexisting inflammation as one critical variable.
In a previous colitis study, it was found that cotransfer of equal numbers of Treg and CD4+CD45RBhigh T cells reduced the systemic expansion of the CD4+CD45RBhigh T cells more efficiently, compared with our data generated by a cotransfer of much higher ratios of CD4+CD45RBhigh T cells:Treg (7). This suggests that Treg are versatile suppressors, and the mode of action and extent of immune suppression caused by Treg transfer could be highly dependent upon the number of cells transferred. Our data indicate that the effects of either the
7+/+ or
7/ Treg were concentrated in the intestine, where the total number of infiltrating CD4+CD45RBhigh T cells was reduced and the ability of the few cells in the intestine to produce Th1 cytokines diminished. These results indicate that in our experiments Treg acted by inhibiting the generation of tissue-seeking Th1 effector cells, which is sufficient to prevent disease in the transfer model of mouse colitis.
| Acknowledgments |
|---|
| Disclosures |
|---|
|
|
|---|
| Footnotes |
|---|
1 This work was supported by National Institutes of Health Grants PO1 DK46763 and RO1 AI 65016 (to M.K). T.L.D. is a recipient of a Jeane B. Kempner Scholarship from the University of Texas Medical Branch at Galveston. G.K. is the recipient of a Career Development Award from the Crohns & Colitis Foundation of America. ![]()
2 This is publication number 677 from the La Jolla Institute for Allergy & Immunology. ![]()
3 T.L.D. and G.K. contributed equally to this work. ![]()
4 Address correspondence and reprint requests to Dr. Mitchell Kronenberg, Division of Developmental Immunology, La Jolla Institute for Allergy and Immunology, 10355 Science Center Drive, San Diego, CA 92121. E-mail address: mitch{at}liai.org ![]()
5 Abbreviations used in this paper: Treg, regulatory T cell; MLN, mesenteric lymph node; LIEL, large intestine intraepithelial lymphocyte; LLPL, large intestine lamina propria lymphocyte. ![]()
Received for publication January 20, 2005. Accepted for publication April 8, 2005.
| References |
|---|
|
|
|---|
1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice. J. Immunol. 172: 834-842.
but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RBlow CD4+ T cells. J. Exp. Med. 183: 2669-2674.
4
7 and LFA-1 in lymphocyte homing to Peyers patch-HEV in situ: the multistep model confirmed and refined. Immunity 3: 99-108.[Medline]
E (CD103)-deficient mice. J. Immunol. 162: 6641-6649.
E
7 mediates adhesion of T lymphocytes to epithelial cells. J. Immunol. 150: 3459-3470.[Abstract]
E
7 integrin. Nature 372: 190-193.[Medline]
7 integrins in formation of the gut-associated lymphoid tissue. Nature 382: 366-370.[Medline]
7 Integrin expression is not required for the localization of T cells to the intestine and colitis pathogenesis. Clin. Exp. Immunol. 129: 35-42.[Medline]
7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells. J. Immunol. 158: 2099-2106.[Abstract]
E
7 identifies unique subsets of CD25+ as well as CD25 regulatory T cells. Proc. Natl. Acad. Sci. USA. 99: 13031-13036.This article has been cited by other articles:
![]() |
T. Totsuka, T. Kanai, Y. Nemoto, T. Tomita, R. Okamoto, K. Tsuchiya, T. Nakamura, N. Sakamoto, H. Akiba, K. Okumura, et al. RANK-RANKL Signaling Pathway Is Critically Involved in the Function of CD4+CD25+ Regulatory T Cells in Chronic Colitis J. Immunol., May 15, 2009; 182(10): 6079 - 6087. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Q. Van, J. Darwiche, M. Raymond, S. Lesage, S. Bouguermouh, M. Rubio, and M. Sarfati Cutting Edge: CD47 Controls the In Vivo Proliferation and Homeostasis of Peripheral CD4+CD25+Foxp3+ Regulatory T Cells That Express CD103 J. Immunol., October 15, 2008; 181(8): 5204 - 5208. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Dudda, N. Perdue, E. Bachtanian, and D. J. Campbell Foxp3+ regulatory T cells maintain immune homeostasis in the skin J. Exp. Med., July 7, 2008; 205(7): 1559 - 1565. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Reardon, A. Wang, and D. M. McKay Transient Local Depletion of Foxp3+ Regulatory T Cells during Recovery from Colitis via Fas/Fas Ligand-Induced Death J. Immunol., June 15, 2008; 180(12): 8316 - 8326. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Atanackovic, Y. Cao, T. Luetkens, J. Panse, C. Faltz, J. Arfsten, K. Bartels, C. Wolschke, T. Eiermann, A. R. Zander, et al. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation Haematologica, March 1, 2008; 93(3): 423 - 430. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-E. Ghia, P. Blennerhassett, and S. M. Collins Vagus nerve integrity and experimental colitis Am J Physiol Gastrointest Liver Physiol, September 1, 2007; 293(3): G560 - G567. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Nummer, E. Suri-Payer, H. Schmitz-Winnenthal, A. Bonertz, L. Galindo, D. Antolovich, M. Koch, M. Buchler, J. Weitz, V. Schirrmacher, et al. Role of Tumor Endothelium in CD4+CD25+ Regulatory T Cell Infiltration of Human Pancreatic Carcinoma J Natl Cancer Inst, August 1, 2007; 99(15): 1188 - 1199. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Yuan, S. K. Bromley, T. K. Means, K. J. Jones, F. Hayashi, A. K. Bhan, and A. D. Luster CCR4-dependent regulatory T cell function in inflammatory bowel disease J. Exp. Med., June 11, 2007; 204(6): 1327 - 1334. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. D. Sather, P. Treuting, N. Perdue, M. Miazgowicz, J. D. Fontenot, A. Y. Rudensky, and D. J. Campbell Altering the distribution of Foxp3+ regulatory T cells results in tissue-specific inflammatory disease J. Exp. Med., June 11, 2007; 204(6): 1335 - 1347. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Eijkelkamp, C. J Heijnen, A. Lucas, R. T Premont, S. Elsenbruch, M. Schedlowski, and A. Kavelaars G protein-coupled receptor kinase 6 controls chronicity and severity of dextran sodium sulphate-induced colitis in mice Gut, June 1, 2007; 56(6): 847 - 854. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Makita, T. Kanai, Y. Nemoto, T. Totsuka, R. Okamoto, K. Tsuchiya, M. Yamamoto, H. Kiyono, and M. Watanabe Intestinal Lamina Propria Retaining CD4+CD25+ Regulatory T Cells Is A Suppressive Site of Intestinal Inflammation J. Immunol., April 15, 2007; 178(8): 4937 - 4946. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Hontecillas and J. Bassaganya-Riera Peroxisome Proliferator-Activated Receptor {gamma} Is Required for Regulatory CD4+ T Cell-Mediated Protection against Colitis J. Immunol., March 1, 2007; 178(5): 2940 - 2949. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Mor, G. Luboshits, D. Planer, G. Keren, and J. George Altered status of CD4+CD25+ regulatory T cells in patients with acute coronary syndromes Eur. Heart J., November 1, 2006; 27(21): 2530 - 2537. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Tischner, A. Weishaupt, J. v. d. Brandt, N. Muller, N. Beyersdorf, C. W. Ip, K. V. Toyka, T. Hunig, R. Gold, T. Kerkau, et al. Polyclonal expansion of regulatory T cells interferes with effector cell migration in a model of multiple sclerosis Brain, October 1, 2006; 129(10): 2635 - 2647. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Naganuma, E. B. Wiznerowicz, C. M. Lappas, J. Linden, M. T. Worthington, and P. B. Ernst Cutting Edge: Critical Role for A2A Adenosine Receptors in the T Cell-Mediated Regulation of Colitis. J. Immunol., September 1, 2006; 177(5): 2765 - 2769. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Marski, S. Kandula, J. R. Turner, and C. Abraham CD18 Is Required for Optimal Development and Function of CD4+CD25+ T Regulatory Cells J. Immunol., December 15, 2005; 175(12): 7889 - 7897. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |